Intervention Review

You have free access to this content

Pharmacological interventions for pruritus in adult palliative care patients

  1. Carola Xander1,*,
  2. Joerg J Meerpohl1,
  3. Daniel Galandi2,
  4. Sabine Buroh3,
  5. Guido Schwarzer1,
  6. Gerd Antes1,
  7. Gerhild Becker4

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 9 JUN 2013

Assessed as up-to-date: 1 APR 2013

DOI: 10.1002/14651858.CD008320.pub2


How to Cite

Xander C, Meerpohl JJ, Galandi D, Buroh S, Schwarzer G, Antes G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD008320. DOI: 10.1002/14651858.CD008320.pub2.

Author Information

  1. 1

    Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg, German Cochrane Centre, Freiburg, Germany

  2. 2

    University Medical Center Freiburg, Department of Oncology and Haematology and Stem Cell Transplantation, Freiburg, Germany

  3. 3

    University Medical Center, Library of the Surgical Clinic, Freiburg, Germany

  4. 4

    University Medical Center, Department of Palliative Care, Freiburg, Germany

*Carola Xander, German Cochrane Centre, Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg, Robert-Koch-Straße 3, Freiburg, 79106, Germany. carola.xander@uniklinik-freiburg.de.

Publication History

  1. Publication Status: New
  2. Published Online: 9 JUN 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Naltrexone versus placebo or standard medication, Outcome 1 Pruritus on VAS scale (CKDP/UP and CP).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Naltrexone versus placebo or standard medication, Outcome 2 Pruritus on VAS scale (CKDP/UP vs. CP - subgroup analysis by nature of pruritus).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Naltrexone versus placebo or standard medication, Outcome 3 Pruritus on VAS scale (subgroup analysis by study design).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Naltrexone versus placebo or standard medication, Outcome 4 Pruritus on VAS scale (CKDP/UP and CP) - sensitivity analysis - statistical model.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Nalfurafine versus placebo, Outcome 1 Pruritus on VAS scale (CKDP/UP).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Nalfurafine versus placebo, Outcome 2 Pruritus on VAS scale (CKDPUP) - sensitivity analysis - statistical model.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 1 Ondansetron versus placebo (CKDP/UP and CP) - pruritus on VAS scale.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 2 Ondansetron versus cyproheptadine (CKDP/UP) - pruritus on scale by Duo/Mettang.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 3 Pruritus on VAS scale - subgroup analysis by nature of pruritus (CKDP/UP).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 4 Pruritus on VAS scale - subgroup analysis by nature of pruritus (CP).
[Analysis 3.5]
Analysis 3.5. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 5 Ondansetron (CP and CKDP/UP; different scales).
[Analysis 3.6]
Analysis 3.6. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 6 Pruritus on VAS scale (CKDP/UP and CP) - sensitivity analysis - statistical model.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Ondansetron versus placebo or standard medication, Outcome 7 Pruritus on different scales (CKDP/UP and CP) - sensitivity analysis - statistical model.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Gabapentin versus placebo, Outcome 1 Gabapenten versus placebo (CKDP/UP).
[Analysis 4.2]
Analysis 4.2. Comparison 4 Gabapentin versus placebo, Outcome 2 Gabapentin versus placebo (CKDP/UP) - sensitivity analysis - statistical model.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Rifampin or rifampicin versus placebo or standard medication, Outcome 1 Rifampin/Rifampicin versus placebo/standard medication.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Rifampin or rifampicin versus placebo or standard medication, Outcome 2 Rifampin/Rifampicin versus placebo/standard medication.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Rifampin or rifampicin versus placebo or standard medication, Outcome 3 Rifampin versus placebo/standard medication - sensitivity analysis - statistical model.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Topical capsaicin versus placebo, Outcome 1 Capsaicin versus placebo.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Topical capsaicin versus placebo, Outcome 2 Capsaicin versus placebo - sensitivity analysis - statistical model.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Secondary outcomes: Patient satisfaction, Outcome 1 Patient satisfaction (Paroxetine versus placebo).
[Analysis 7.2]
Analysis 7.2. Comparison 7 Secondary outcomes: Patient satisfaction, Outcome 2 Patient satisfaction (paroxetine versus placebo) - sensitivity analysis - statistical model.